Poulton Jeffrey V. (CIK 1782962) reported 67 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-03-06). Recent activity: Sell ALNY (114 shares), Sell ALNY (109 shares), Sell ALNY (230 shares), Sell ALNY (309 shares), Sell ALNY (374 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 114 | $36,369 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 109 | $34,881 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 230 | $73,786 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 309 | $99,442 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 374 | $120,806 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 818 | $264,901 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 291 | $94,540 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 223 | $72,624 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 541 | $176,804 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 65 | $21,035 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 124 | $40,257 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 356 | $115,924 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Buy | 4,769 | $0 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 454 | $148,762 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 138 | $45,362 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 234 | $77,152 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 112 | $37,055 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 129 | $42,819 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 53 | $17,630 |
| 2026-03-02 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Buy | 1,908 | $0 |
| 2026-02-17 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Buy | 4,579 | $0 |
| 2026-02-17 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 2,242 | $695,199 |
| 2026-01-14 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Buy | 6,193 | $0 |
| 2026-01-14 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 72 | $25,484 |
| 2026-01-14 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | EVP, Chief Financial Officer | Sell | 78 | $27,702 |
Source: SEC Form 4 filings · as of 2026-03-06